{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:44:53Z","timestamp":1774896293491,"version":"3.50.1"},"reference-count":129,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR134985"],"award-info":[{"award-number":["NIHR134985"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this National Institute for Health and Care Excellence multiple technology appraisal. A patient\u2019s risk of disease progression depends on a number of prognostic risk factors; patients are categorised as having intermediate\/poor risk or favourable risk of disease progression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objectives<\/jats:title>\n<jats:p>The objectives of this multiple technology appraisal were to appraise the clinical effectiveness and cost-effectiveness of lenvatinib plus pembrolizumab versus relevant comparators listed in the final scope issued by the National Institute for Health and Care Excellence: sunitinib, pazopanib, tivozanib, cabozantinib and nivolumab plus ipilimumab.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Methods<\/jats:title>\n<jats:p>The assessment group carried out clinical and economic systematic reviews and assessed the clinical and cost-effectiveness evidence submitted by Eisai, Hatfield, Hertfordshire, UK (the manufacturer of lenvatinib) and Merck Sharp &amp; Dohme, Whitehouse Station, NJ, USA (the manufacturer of pembrolizumab). The assessment group carried out fixed-effects network meta-analyses using a Bayesian framework to generate evidence for clinical effectiveness. As convergence issues occurred due to sparse data, random-effects network meta-analysis results were unusable. The assessment group did not develop a de novo economic model, but instead modified the partitioned survival model provided by Merck Sharp &amp; Dohme.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Results<\/jats:title>\n<jats:p>The assessment group clinical systematic review identified one relevant randomised controlled trial (CLEAR trial). The CLEAR trial is a good-quality, phase III, multicentre, open-label trial that provided evidence for the efficacy and safety of lenvatinib plus pembrolizumab compared with sunitinib.<\/jats:p>\n<jats:p>The assessment group progression-free survival network meta-analysis results for all three risk groups should not be used to infer any statistically significant difference (or lack of statistically significant difference) for any of the treatment comparisons owing to within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption. The assessment group overall survival network meta-analysis results for the intermediate-\/poor-risk subgroup suggested that there was a numerical, but not statistically significant, improvement in the overall survival for patients treated with lenvatinib plus pembrolizumab compared with patients treated with cabozantinib or nivolumab plus ipilimumab. Because of within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption, the assessment group overall survival network meta-analysis results for the favourable-risk subgroup and the all-risk population should not be used to infer any statistically significant difference (or lack of statistically significant difference) for any of the treatment comparisons.<\/jats:p>\n<jats:p>Only one cost-effectiveness study was included in the assessment group review of cost-effectiveness evidence. The study was limited to the all-risk population, undertaken from the perspective of the US healthcare system and included comparators that are not recommended by the National Institute for Health and Care Excellence for patients with untreated advanced renal cell carcinoma. Therefore, the extent to which resource use and results are generalisable to the NHS is unclear.<\/jats:p>\n<jats:p>The assessment group cost-effectiveness results from the modified partitioned survival model focused on the intermediate-\/poor-risk and favourable-risk subgroups. The assessment group cost-effectiveness results, generated using list prices for all drugs, showed that, for all comparisons in the favourable-risk subgroup, treatment with lenvatinib plus pembrolizumab costs more and generated fewer benefits than all other treatments available to NHS patients. For the intermediate-\/poor-risk subgroup, treatment with lenvatinib plus pembrolizumab costs more and generated more benefits than treatment with cabozantinib and nivolumab plus ipilimumab.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Conclusions<\/jats:title>\n<jats:p>Good-quality clinical effectiveness evidence for the comparison of lenvatinib plus pembrolizumab with sunitinib is available from the CLEAR trial. For most of the assessment group Bayesian hazard ratio network meta-analysis comparisons, it is difficult to reach conclusions due to within-trial proportional hazards violations or uncertainty regarding the validity of the proportional hazards assumption. However, the data (clinical effectiveness and cost-effectiveness) used to populate the economic model are relevant to NHS clinical practice and can be used to inform National Institute for Health and Care Excellence decision-making. The assessment group cost-effectiveness results, generated using list prices for all drugs, show that lenvatinib plus pembrolizumab is less cost-effective than all other treatment options.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Study registration<\/jats:title>\n<jats:p>This study is registered as PROSPERO CRD4202128587.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-7\"><jats:title>Funding<\/jats:title>\n<jats:p>This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis Programme (NIHR award ref: NIHR134985) and is published in full in <jats:italic>Health Technology Assessment<\/jats:italic>; Vol. 28, No. 49. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/trrm4238","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:15:37Z","timestamp":1725956137000},"page":"1-190","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-9779","authenticated-orcid":true,"given":"Nigel","family":"Fleeman","sequence":"first","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-7732","authenticated-orcid":true,"given":"Rachel","family":"Houten","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-2709","authenticated-orcid":true,"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-1003","authenticated-orcid":true,"given":"James","family":"Mahon","sequence":"additional","affiliation":[{"name":"Coldingham Analytical Services, Berwickshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-103X","authenticated-orcid":true,"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[{"name":"Hare Research, North Yorkshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-8644","authenticated-orcid":true,"given":"Angela","family":"Boland","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-1904","authenticated-orcid":true,"given":"Janette","family":"Greenhalgh","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0092","authenticated-orcid":true,"given":"Katherine","family":"Edwards","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4419-6343","authenticated-orcid":true,"given":"Michelle","family":"Maden","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1694-8106","authenticated-orcid":true,"given":"Devarshi","family":"Bhattacharyya","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-8704","authenticated-orcid":true,"given":"Marty","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7486-4018","authenticated-orcid":true,"given":"Joanne","family":"McEntee","sequence":"additional","affiliation":[{"name":"North West Medicines Information Centre, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-1297","authenticated-orcid":true,"given":"Shien","family":"Chow","sequence":"additional","affiliation":[{"name":"The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-3829","authenticated-orcid":true,"given":"Tom","family":"Waddell","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2024,8]]},"reference":[{"key":"key2024091013410500_ref3-bib3","volume-title":"Lenvatinib with Pembrolizumab for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA858]","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2024091013410500_ref4-bib4","first-page":"45","article-title":"Renal cell carcinoma: links and risks","volume":"9","author":"Kabaria","year":"2016","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"key2024091013410500_ref5-bib5","volume-title":"Types and grades. Kidney cancer","author":"Cancer Research UK","year":"2020"},{"key":"key2024091013410500_ref6-bib6","volume-title":"Renal Cell Carcinoma","author":"BMJ Best Practice"},{"key":"key2024091013410500_ref7-bib7","first-page":"179","article-title":"Renal cell carcinoma: diagnosis and management","volume":"99","author":"Gray","year":"2019","journal-title":"Am Fam Physician"},{"key":"key2024091013410500_ref8-bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"key2024091013410500_ref9-bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000495366","article-title":"Non-clear cell renal cell carcinoma \u2013 pathology and treatment options","volume":"42","author":"Ahrens","year":"2019","journal-title":"Oncol Res Treat"},{"key":"key2024091013410500_ref10-bib10","first-page":"308","article-title":"Non-clear cell renal cell carcinoma, part 1: histology","volume":"13","author":"Valenca","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"key2024091013410500_ref11-bib11","volume-title":"Kidney Cancer Stages. Renal Cell Carcinoma Staging","author":"American Cancer Society","year":"2020"},{"key":"key2024091013410500_ref12-bib12","volume-title":"Kidney Cancer Incidence Statistics","author":"Cancer Research UK","year":"2020"},{"key":"key2024091013410500_ref13-bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref14-bib14","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref15-bib15","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref16-bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"key2024091013410500_ref17-bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11523-015-0366-9","article-title":"Comparison of two prognostic models in patients with metastatic renal cancer treated with sunitinib: a retrospective, registry-based study","volume":"10","author":"Kubackova","year":"2015","journal-title":"Target Oncol"},{"key":"key2024091013410500_ref18-bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12885-016-2395-x","article-title":"Variation in use of targeted therapies for metastatic renal cell carcinoma: results from a Dutch population-based registry","volume":"16","author":"de Groot","year":"2016","journal-title":"BMC Cancer"},{"key":"key2024091013410500_ref19-bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040808","article-title":"Outcomes according to MSKCC risk score with focus on the intermediate-risk group in metastatic renal cell carcinoma patients treated with first-line sunitinib: a retrospective analysis of 2390 patients","volume":"12","author":"Fiala","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key2024091013410500_ref20-bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"key2024091013410500_ref21-bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1634\/theoncologist.2019-0605","article-title":"Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the International mRCC Database Consortium Risk Group","volume":"25","author":"Savard","year":"2020","journal-title":"Oncologist"},{"key":"key2024091013410500_ref22-bib22","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.21873\/invivo.11422","article-title":"mRCC outcome in the treatment of metastatic renal cell carcinoma \u2013 a German single-center real-world experience","volume":"32","author":"Schwab","year":"2018","journal-title":"In Vivo"},{"key":"key2024091013410500_ref23-bib23","doi-asserted-by":"crossref","first-page":"27752","DOI":"10.18632\/oncotarget.25554","article-title":"The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria","volume":"9","author":"Tamada","year":"2018","journal-title":"Oncotarget"},{"key":"key2024091013410500_ref24-bib24","volume-title":"Cabozantinib for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA542]","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2024091013410500_ref25-bib25","volume-title":"Nivolumab with Ipilimumab for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA581]","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2024091013410500_ref26-bib26","volume-title":"Cancer Survival in England: Adult, Stage at Diagnosis and Childhood \u2013 Patients Followed up to 2018","author":"Office for National Statistics"},{"key":"key2024091013410500_ref27-bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref28-bib28","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref29-bib29","volume-title":"Final Scope for the Appraisal of Lenvatinib with Pembrolizumab for Untreated Advanced Renal Cell Carcinoma","author":"National Institute for Health and Care Excellence","year":"2021"},{"key":"key2024091013410500_ref30-bib30","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"key2024091013410500_ref31-bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1464-410x.1999.00202.x","article-title":"Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy","volume":"84","author":"Ljungberg","year":"1999","journal-title":"BJU Int"},{"key":"key2024091013410500_ref32-bib32","volume-title":"Sunitinib for the First-line Treatment of Advanced and\/or Metastatic Renal Cell Carcinoma. Technology Appraisal Guidance [TA169]","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"key2024091013410500_ref33-bib33","volume-title":"Pazopanib for the First-Line Treatment of Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA215]","author":"National Institute for Health and Care Excellence","year":"2011"},{"key":"key2024091013410500_ref34-bib34","volume-title":"Tivozanib for Treating Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA512]","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2024091013410500_ref35-bib35","volume-title":"Avelumab with Axitinib for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA645]","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2024091013410500_ref36-bib36","volume-title":"Nivolumab with Ipilimumab for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA780]","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2024091013410500_ref37-bib37","volume-title":"Pembrolizumab with Axitinib for Untreated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA650]","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key2024091013410500_ref38-bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor\u2013based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur Urol"},{"key":"key2024091013410500_ref39-bib39","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"key2024091013410500_ref40-bib40","volume-title":"Bevacizumab (First-Line), Sorafenib (First- and Second-Line), Sunitinib (Second-Line) and Temsirolimus (First-Line) for the Treatment of Advanced and\/or Metastatic Renal Cell Carcinoma. Technology Appraisal Guidance [TA178]","author":"National Institute for Health and Care Excellence","year":"2009"},{"key":"key2024091013410500_ref41-bib41","volume-title":"Nivolumab with Cabozantinib for Untreated Advanced or Metastatic Renal Cell Carcinoma [TA785]","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2024091013410500_ref42-bib42","volume-title":"Axitinib for Treating Advanced Renal Cell Carcinoma after Failure of Prior Systemic Treatment. Technology Appraisal Guidance [TA333]","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2024091013410500_ref43-bib43","volume-title":"Cabozantinib for previously Treated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA463]","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key2024091013410500_ref44-bib44","volume-title":"Lenvatinib with Everolimus for Previously Treated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA498]","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"key2024091013410500_ref45-bib45","volume-title":"Summary of Product Characteristics: Kisplyx 4\u2009mg Hard Capsules","author":"Eisai Ltd"},{"key":"key2024091013410500_ref46-bib46","volume-title":"Summary of Product Characteristics: KEYTRUDA\u00ae 25\u2009mg\/mL Concentrate for Solution for Infusion","author":"Merck Sharp & Dohme (UK) Limited"},{"key":"key2024091013410500_ref47-bib47","volume-title":"Nivolumab for Previously Treated Advanced Renal Cell Carcinoma. Technology Appraisal Guidance [TA417]","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"key2024091013410500_ref48-bib48","volume-title":"Everolimus for Advanced Renal Cell Carcinoma after Previous Treatment. Technology Appraisal Guidance [TA432]","author":"National Institute for Health and Care Excellence","year":"2017"},{"key":"key2024091013410500_ref49-bib49","volume-title":"Summary of Product Characteristics: CABOMETYX 20 mg Film-coated tablets, CABOMETYX 40 mg Film-coated tablets, CABOMETYX 60 mg Film-coated tablets","author":"Ipsen Ltd"},{"key":"key2024091013410500_ref50-bib50","volume-title":"Summary of Product Characteristics: Inlyta 1\u2009mg Film-Coated Tablets","author":"Pfizer Limited"},{"key":"key2024091013410500_ref51-bib51","volume-title":"Summary of Product Characteristics: Bavencio 20\u2009mg\/mL Concentrate for Solution for Infusion","author":"Merck Sharp & Dohme (UK) Limited"},{"key":"key2024091013410500_ref52-bib52","volume-title":"Summary of Product Characteristics: OPDIVO 10\u2009mg\/mL Concentrate for Solution for Infusion","author":"Bristol-Myers Squibb Pharmaceuticals Limited"},{"key":"key2024091013410500_ref53-bib53","doi-asserted-by":"crossref","first-page":"102295","DOI":"10.1016\/j.ctrv.2021.102295","article-title":"Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis","volume":"100","author":"Ciccarese","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key2024091013410500_ref54-bib54","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur J Cancer"},{"key":"key2024091013410500_ref55-bib55","doi-asserted-by":"crossref","first-page":"102242","DOI":"10.1016\/j.ctrv.2021.102242","article-title":"Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"99","author":"Mori","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"key2024091013410500_ref56-bib56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JU.0000000000002252","article-title":"Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"207","author":"Nocera","year":"2021","journal-title":"J Urology"},{"key":"key2024091013410500_ref57-bib57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"key2024091013410500_ref58-bib58","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MOU.0000000000000889","article-title":"Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis","volume":"31","author":"Quhal","year":"2021","journal-title":"Curr Opin Urol"},{"key":"key2024091013410500_ref59-bib59","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/KCA-210120","article-title":"First-line immunotherapy combinations in advanced renal cell carcinoma: a rapid review and meta-analysis","volume":"5","author":"Shpilsky","year":"2021","journal-title":"Kidney Cancer"},{"key":"key2024091013410500_ref61-bib61","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Med"},{"key":"key2024091013410500_ref62-bib62","volume-title":"Process of Information Retrieval for Systematic Reviews and Health Technology Assessments on Clinical Effectiveness","author":"European network for Health Technology Assessment (EUnetHTA)","year":"2019"},{"key":"key2024091013410500_ref64-bib64","volume-title":"Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia"},{"key":"key2024091013410500_ref65-bib65","volume-title":"Position Statement: Consideration of Products Recommended for Use in the Cancer Drugs Fund as Comparators, or in a Treatment Sequence, in the Appraisal of a New Cancer Product","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"key2024091013410500_ref66-bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"New Engl J Med"},{"key":"key2024091013410500_ref67-bib67","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2021.08.056","article-title":"Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): outcomes in subgroups and toxicity update","volume":"32","author":"Choueiri","year":"2021","journal-title":"Ann Oncol"},{"key":"key2024091013410500_ref75-bib75","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2217\/fon-2018-0745","article-title":"Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale","volume":"15","author":"Grunwald","year":"2019","journal-title":"Future Oncol"},{"key":"key2024091013410500_ref76-bib76","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2021.39.15_suppl.4560","article-title":"Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms","volume":"39","author":"Grunwald","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref77-bib77","volume-title":"Lenvatinib\/Everolimus or Lenvatinib\/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma","author":"JapicCTI"},{"key":"key2024091013410500_ref78-bib78","first-page":"TPS4595","article-title":"A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). J Clin Oncol","volume":"35","author":"Motzer","year":"2017"},{"key":"key2024091013410500_ref79-bib79","first-page":"169","article-title":"A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma (RCC)","volume":"13","author":"Motzer","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"key2024091013410500_ref80-bib80","doi-asserted-by":"crossref","first-page":"TPS4595","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4595","article-title":"A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref81-bib81","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2021.39.15_suppl.4502","article-title":"Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref82-bib82","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.2021.39.6_suppl.269","article-title":"Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref83-bib83","volume-title":"Lenvatinib\/Everolimus or Lenvatinib\/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma","author":"Nct","year":"2016"},{"key":"key2024091013410500_ref84-bib84","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref85-bib85","unstructured":"Latimer NR, Abrams KR. NICE DSU Technical Support Document 16. Adjusting Survival Time Estimates in the Presence of Treatment Switching. [Commissioned report]. National Institute for Health and Clinical Excellence. 2014. URL: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD16_Treatment_Switching.pdf (accessed July 2021)."},{"key":"key2024091013410500_ref86-bib86","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"key2024091013410500_ref87-bib87","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","author":"US Department of Health and Human Services, National Institutes of Health National Cancer Institute","year":"2009"},{"key":"key2024091013410500_ref88-bib88","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jcpt.13282","article-title":"A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma","volume":"46","author":"Heo","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"key2024091013410500_ref89-bib89","first-page":"S2","article-title":"A phase 3 trial to compare efficacy and safety of Lenvatinib in combination with Everolimus or Pembrolizumab vs Sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma","volume":"2","author":"Motzer","year":"2018","journal-title":"Kidney Cancer"},{"key":"key2024091013410500_ref90-bib90","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s12325-019-01167-2","article-title":"Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis","volume":"37","author":"Manz","year":"2020","journal-title":"Adv Ther"},{"key":"key2024091013410500_ref91-bib91","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.21037\/apm-20-1884","article-title":"Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"key2024091013410500_ref92-bib92","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3390\/cancers12061673","article-title":"Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"12","author":"Elaidi","year":"2020","journal-title":"Cancers"},{"key":"key2024091013410500_ref93-bib93","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/COC.0000000000000695","article-title":"Combination therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"43","author":"Alam","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"key2024091013410500_ref94-bib94","doi-asserted-by":"crossref","first-page":"e034626","DOI":"10.1136\/bmjopen-2019-034626","article-title":"What is the optimum systemic treatment for advanced\/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis","volume":"10","author":"Cao","year":"2020","journal-title":"BMJ Open"},{"key":"key2024091013410500_ref95-bib95","doi-asserted-by":"crossref","first-page":"1758835920950199","DOI":"10.1177\/1758835920950199","article-title":"First-line treatments for advanced renal-cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"12","author":"Su","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"key2024091013410500_ref96-bib96","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Riaz","year":"2021","journal-title":"Eur Urol"},{"key":"key2024091013410500_ref97-bib97","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2018.02.012","article-title":"Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update","volume":"94","author":"Choueiri","year":"2018","journal-title":"Eur J Cancer"},{"key":"key2024091013410500_ref98-bib98","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"Eur Urol"},{"key":"key2024091013410500_ref99-bib99","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref100-bib100","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key2024091013410500_ref101-bib101","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref102-bib102","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref103-bib103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","article-title":"SWITCH II: phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","volume":"107","author":"Retz","year":"2019","journal-title":"Eur J Cancer"},{"key":"key2024091013410500_ref104-bib104","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.clgc.2020.01.001","article-title":"Sunitinib versus sorafenib as initial targeted therapy for mCC-RCC with favorable\/intermediate risk: multicenter randomized trial CROSS-J-RCC","volume":"18","author":"Tomita","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"key2024091013410500_ref105-bib105","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref106-bib106","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"key2024091013410500_ref107-bib107","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B Stat Methodol"},{"key":"key2024091013410500_ref108-bib108","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/09622802211070253","article-title":"Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making: application to a melanoma network","volume":"31","author":"Freeman","year":"2022","journal-title":"Stat Methods Med Res"},{"key":"key2024091013410500_ref109-bib109","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.jval.2018.09.2339","article-title":"PRM221 \u2013 network meta-analysis in the presence of non-proportionality: a review of NICE submissions","volume":"21","author":"Le Moine","year":"2018","journal-title":"Value Health"},{"key":"key2024091013410500_ref110-bib110","volume-title":"DIC: Deviance Information Criteria","author":"Medical Research Council (MRC) Biostatistics Unit (BSU)"},{"key":"key2024091013410500_ref111-bib111","volume-title":"Multinma: Network Meta-Analysis of Individual and Aggregate Data in Stan","author":"Phillippo","year":"2021"},{"key":"key2024091013410500_ref112-bib112","volume-title":"NICE DSU Technical Support Document 2. A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024091013410500_ref113-bib113","volume-title":"NICE DSU Technical Support Document 3. Heterogeneity: Subgroups, Meta-Regression, Bias and Bias-Adjustment","author":"Dias"},{"key":"key2024091013410500_ref114-bib114","volume-title":"NICE DSU Technical Support Document 4. Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2024091013410500_ref115-bib115","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"key2024091013410500_ref117-bib117","doi-asserted-by":"crossref","first-page":"718014","DOI":"10.3389\/fphar.2021.718014","article-title":"Cost-effectiveness of frontline treatment for advanced renal cell carcinoma in the era of immunotherapies","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"key2024091013410500_ref118-bib118","doi-asserted-by":"crossref","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"key2024091013410500_ref119-bib119","volume-title":"Guide to the Methods of Technology Appraisal 2013. Process and methods [PMG9]","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2024091013410500_ref121-bib121","volume-title":"National Schedule of Reference Costs 2019\/20","author":"NHS","year":"2018"},{"key":"key2024091013410500_ref122-bib122","volume-title":"Exploring the Cost of Care at the End of Life","author":"Georghiou","year":"2014"},{"key":"key2024091013410500_ref123-bib123","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afab282","article-title":"Clinical trials in older people","volume":"51","author":"Pitkala","year":"2022","journal-title":"Age Ageing"},{"key":"key2024091013410500_ref124-bib124","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key2024091013410500_ref125-bib125","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/bcp.14539","article-title":"Underrepresentation of the elderly in clinical trials, time for action","volume":"86","author":"van Marum","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"key2024091013410500_ref126-bib126","volume-title":"Population of England and Wales: GOV.UK Ethnicity Facts and Figures","author":"GOV.UK","year":"2022"},{"key":"key2024091013410500_ref127-bib127","volume-title":"Lenvatinib with Everolimus or Pembrolizumab for Untreated Advanced Renal Cell Carcinoma [ID3760]. In development [GID-TA10629]","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2024091013410500_ref128-bib128","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"key2024091013410500_ref129-bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"key2024091013410500_ref130-bib130","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"key2024091013410500_ref131-bib131","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref132-bib132","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref133-bib133","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref134-bib134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.2017.75.2170","article-title":"Quality of life outcomes for cabozantinib versus everolimus in patients with metastatic renal cell carcinoma: METEOR phase III randomized trial","volume":"36","author":"Cella","year":"2018","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref135-bib135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-017-1704-4","article-title":"Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma","volume":"27","author":"de Groot","year":"2018","journal-title":"Qual Life Res"},{"key":"key2024091013410500_ref136-bib136","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"key2024091013410500_ref137-bib137","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.20.01849","article-title":"Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma","volume":"39","author":"Patel","year":"2021","journal-title":"J Clin Oncol"},{"key":"key2024091013410500_ref138-bib138","volume-title":"Physician Fee Schedule","author":"Centers for Medicare & Medicaid Services","year":"2021"},{"key":"key2024091013410500_ref139-bib139","volume-title":"Healthcare Cost and Utilization Project","author":"Agency for Healthcare Research and Quality, US Department of Health & Human Services","year":"2021"},{"key":"key2024091013410500_ref140-bib140","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"key2024091013410500_ref141-bib141","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3111\/13696998.2014.985789","article-title":"Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US","volume":"18","author":"Perrin","year":"2015","journal-title":"J Med Econ"},{"key":"key2024091013410500_ref142-bib142","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045883","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/TRRM4238\/TRRM4238.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:17:06Z","timestamp":1725956226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/TRRM4238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":129,"alternative-id":["10.3310\/TRRM4238"],"URL":"https:\/\/doi.org\/10.3310\/trrm4238","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"11-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"06-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"02-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}